Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ETX1317
- Development stage
- Unknown
- Lead developer
- Innoviva
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ETX1317 is an investigational **small-molecule diazabicyclooctane serine beta-lactamase inhibitor** developed by Entasis Therapeutics and now associated with Innoviva following Entasis' acquisition. It is the active metabolite of the oral prodrug ETX0282 and is designed to inhibit a broad range of serine beta-lactamases, including class A, class C, and class D enzymes such as CTX-M-15, KPC-2, SHV-5, TEM-1, AmpC, P99, and OXA-48. By reversibly covalently inhibiting these resistance enzymes, ETX1317 restores the activity of partner beta-lactam antibiotics against multidrug-resistant Enterobacterales, including carbapenem-resistant strains. Its clinical development has primarily been in the oral combination of ETX0282 with cefpodoxime proxetil for complicated urinary tract infections and related resistant Gram-negative infections rather than as a standalone marketed product.
- Other names
- ETX1317ETX-1317ETX 1317
02
Targets
OXA (Class D beta-lactamase)AmpC (AmpC beta-lactamase)
Beyond the preview
Go deeper on ETX1317.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ETX1317.